Earlier this week I was with a biotech start-up whose investors have been pondering whether a China strategy makes sense.  Their early focus on China has largely been related to whether they could raise capital from Chinese investors.  While they are a start-up, over $40 million has already been invested.  Their first molecule showed good [...]

According to a report by the Beijing Daily three days ago, Johnson and Johnson, Pfizer, GSK and Harbin Pharmaceutical, are part of a ‘boycott’ of the National Development and Reform Commission’s (NDRC) latest stab at ‘encouraging’ China’s pharmaceutical manufacturers to self-report ex-factory manufacturing prices of their retail drugs for the 2011 fiscal year. It is, however, [...]

This was not the original topic for today’s scheduled column, but over the course of the last 24 hours between Damjan’s column yesterday on the Lin v. Siemens case and its impact on FCPA issues specific to healthcare companies in China, a client conversation, and an email forwarded to me by a friend in China [...]